SCO-267
规格
| Cas Number | 1656261-09-4 |
| 规格或纯度 | ≥99% |
| 纯度 | ≥99% |
| 包装 | 10mg 或 1mg 或 5mg 或 25mg |
产品信息
| 品牌 | 阿拉丁 |
| 过滤标签 | Free Fatty Acid Receptor,GPCR/G Protein |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 生化和生理学机理 | SCO-267 是一种异位 GPR40 完全激动剂。SCO-267 可用于包括糖尿病在内的慢性疾病的研究。 |
| 英文描述 |
SCO-267 is an allosteric GPR40 full agonist. SCO-267 can be used for the research of chronic diseases including diabetes In Vitro SCO-267 (CHO cells) activates the Gα q , Gα s , and Gα 12/13 pathways and β-Arrestin Recruitment. SCO-267 is allosteric with fasiglifam and an endogenous ligand. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo SCO-267 (1 or 10 mg/kg; p.o.) improves insulin sensitivity and exerts sustained glucose-lowering effect . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: N-STZ rats Dosage: 1 or 10 mg/kg Administration: P.o.; Result: Improved insulin sensitivity and exerted sustained glucose-lowering effect. Form:Solid IC50& Target:GPR40 |